Parkinson's disease (PD) is a widespread neurodegenerative condition [1]; however, its association with glycolysis, specifically the activity of genes related to glycolysis, has not yet been explored. We downloaded 3 datasets related to PD from the GEO database and identified the glycolytic genes related to PD. Subsequently, GO and KEGG enrichment analyses were conducted. We constructed a PD diagnosis model using the SVM algorithm for differentially expressed glycolysis-related genes and verified the model with LASSO regression analysis. Next, we constructed a regulatory network of genes that were differentially expressed with respect to glycolysis. Finally, the amount of immune cell infiltration was analyzed in PD samples, and the correlation between differential genes and immune cells was calculated. A total of 64 differentially expressed glycolytic genes associated with PD were screened. Then, a GO analysis was conducted, followed by KEGG and GASE enrichment analyses. Within the established PD diagnostic model, 26 genes that were differentially expressed and linked to glycolysis showed strong statistical significance. After further screening, a diagnostic model for PD including seven key genes was established. Further analysis showed that ABHD5 most strongly correlated with neutrophils (r = 0.507). The key gene SMAD3 was strongly negatively associated with gamma delta T cells (r = −0.488). This research offered a theoretical foundation for the association between glycolysis and PD. Seven glycolytic genes were identified as significantly linked to PD and warrant additional research.

Aims We aim to find out the factors affecting the use of anticoagulants and the intensity of their choices, and to establish a basis for improving neurologists' effective implementation of the guidelines. Methods A cross‐sectional study is conducted in Hubei province in central China. Each neurologist completes a standard‐structured anonymous questionnaire through face‐to‐face interviews. The problems include the attitude and options about anticoagulant therapy. Results A total of 611 neurologists from 38 hospitals respond to this survey. For the best treatment of atrial fibrillation, more than 80% of physicians choose anticoagulant therapy. For patients with atrial fibrillation and cerebral infarction, physicians think Warfarin is the preferred drug as high as 93.8%. Among the anticoagulant drugs ever used by clinicians, the use rate of Warfarin is 93.8%, but the use rate of direct oral anticoagulants is insufficient. The use of direct oral anticoagulants is related to the educational level and the geographical location of the hospital. Bleeding risk is the first reason influencing clinicians' choice of Warfarin, accounts for 88.9%. 97.7% of the clinicians recommend patients with Warfarin regularly monitoring the INR, but the frequency of monitoring is inconsistent. Clinicians have a high willingness to learn about AF, but the proportion of hospitals carry out appropriate training is low. Conclusions There are still some gaps with the guidelines on the choice of anticoagulant drugs. Neurologists have positive attitude towards anticoagulant therapy and a strong willingness to learn, but the corresponding training is lacking. Continuous professional training is necessary.